Figure 5.
Asciminib, ponatinib and HU synergize in counteracting the growth of primary CML cells. Primary neoplastic cells isolated from 3 patients with CP CML (A: Patients #1, #3 and #4; B: Patients #2, #6 and #7) were kept in control medium or in the presence of asciminib, ponatinib, HU, or drug-combinations as indicated for 48 hours before 3H-thymidine-uptake was evaluated. Results are expressed as percent of control and represent the mean ± S.D. of three patients. Asterisk: P<0.05 compared to control medium. Patients’ numbers refer to Table 1.